J Blay

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
    I Ray-Coquard
    Centre L Bérand, Lyon, France
    Br J Cancer 88:181-6. 2003
  2. pmc Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
    A Dufresne
    Department of Medical Oncology and Department of Pathological Anatomy, Hospital Edouard Herrriot, Lyon, France
    Br J Cancer 103:482-5. 2010
  3. doi request reprint Trabectedin's contribution to the treatment of sarcomas
    Jean Yves Blay
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Expert Rev Anticancer Ther 13:3-9. 2013
  4. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
  5. pmc Validation of prognostic scores for survival in cancer patients beyond first-line therapy
    Olivier Tredan
    Universite de Lyon, Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    BMC Cancer 11:95. 2011
  6. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
  7. pmc CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways
    Nathalie Voorzanger-Rousselot
    Equipe Cytokines et Cancer, Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    BMC Cancer 6:75. 2006
  8. pmc Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
    Antoine Lurkin
    Centre Leon Berard, Lyon, France
    BMC Cancer 10:150. 2010
  9. pmc Impact of organised programs on colorectal cancer screening
    Francois Eisinger
    Paoli Calmettes Institute INSERM UMR599 232 Bd, St Marguerite, 13009 Marseille, France
    BMC Cancer 8:104. 2008
  10. ncbi request reprint [Neoadjuvant chemotherapy in sarcoma]
    Jean Yves Blay
    Hôpital Edouard Herriot et Unité Inserm U590, Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 93:1093-8. 2006

Detail Information

Publications117 found, 100 shown here

  1. pmc Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
    I Ray-Coquard
    Centre L Bérand, Lyon, France
    Br J Cancer 88:181-6. 2003
    ..The 'day 1' model identifies a small population of patients at high risk for FN, but has a lower sensitivity than the day 5 model...
  2. pmc Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
    A Dufresne
    Department of Medical Oncology and Department of Pathological Anatomy, Hospital Edouard Herrriot, Lyon, France
    Br J Cancer 103:482-5. 2010
    ..Imatinib induces responses and disease stabilisations in non-resectable patients with aggressive fibromatosis (AF). The precise target of imatinib in AF and predictive factors for response to treatment are unknown...
  3. doi request reprint Trabectedin's contribution to the treatment of sarcomas
    Jean Yves Blay
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Expert Rev Anticancer Ther 13:3-9. 2013
    ..Numerous clinical studies currently underway with trabectedin are aiming to resolve a variety of questions in order to optimize its use in clinical practice...
  4. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
    ..Chemokines CCL19, CCL20 and CCL21 and their receptors CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer...
  5. pmc Validation of prognostic scores for survival in cancer patients beyond first-line therapy
    Olivier Tredan
    Universite de Lyon, Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    BMC Cancer 11:95. 2011
    ..We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for advanced or metastatic cancer after first-line treatment...
  6. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
    ..We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial...
  7. pmc CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways
    Nathalie Voorzanger-Rousselot
    Equipe Cytokines et Cancer, Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    BMC Cancer 6:75. 2006
    ..CD40L was found to reduce doxorubicin-induced apoptosis in non Hodgkin's lymphoma cell lines through caspase-3 dependent mechanism. Whether this represents a general mechanism for other tumor types is unknown...
  8. pmc Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
    Antoine Lurkin
    Centre Leon Berard, Lyon, France
    BMC Cancer 10:150. 2010
    ..We prospectively assessed the medical management of all patients diagnosed with sarcoma in a European region over a one-year period to identify the quantity of first diagnosis compared to central expert review (CER)...
  9. pmc Impact of organised programs on colorectal cancer screening
    Francois Eisinger
    Paoli Calmettes Institute INSERM UMR599 232 Bd, St Marguerite, 13009 Marseille, France
    BMC Cancer 8:104. 2008
    ..Colorectal cancer (CRC) screening has been shown to decrease CRC mortality. Organised mass screening programs are being implemented in France. Its perception in the general population and by general practitioners is not well known...
  10. ncbi request reprint [Neoadjuvant chemotherapy in sarcoma]
    Jean Yves Blay
    Hôpital Edouard Herriot et Unité Inserm U590, Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 93:1093-8. 2006
    ..In elderly and/or frail patients, conversely, single agent doxorubicin may be the preferred option...
  11. ncbi request reprint Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group
    Jean Yves Blay
    Unité INSERM U590 Centre Léon Bérard and Université Claude Bernard Lyon I and Hopital Edouard Herriot, Lyon, France
    J Clin Oncol 25:1107-13. 2007
    ..Imatinib is the standard treatment of advanced GI stromal tumors (GISTs). It is not known whether imatinib may be stopped in patients in whom disease is controlled...
  12. ncbi request reprint Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE)
    Jean Yves Blay
    Hopital Edouard Herriot, Oncologie Médicale, Pavillon E, 5 Place d Arsonval, 69437 Lyon Cedex 03, France
    Crit Rev Oncol Hematol 64:106-14. 2007
    ....
  13. ncbi request reprint Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
    J Y Blay
    Unité Inserm 590, Centre Leon Berard, 69008 Lyon and Hopital Edouard Herriot, Place d Arsonval, 69003 Lyon, France
    Ann Oncol 16:566-78. 2005
    ..The objectives of this international consensus meeting were to describe the optimal management procedures for patients with GIST in localized and advanced stages, as well as research issues for the future...
  14. pmc Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma
    Jean Yves Blay
    CONTICANET and UJOMM Hôpital Edouard Herrot, Centre Leon Berard, Lyon, France
    Clin Cancer Res 14:6656-62. 2008
    ..Blood was collected during cycle 1 for pharmacokinetic analyses. Adverse events, tumor response, and survival were assessed...
  15. ncbi request reprint [Targeted therapies of cancer: not lost in translation]
    Jean Yves Blay
    Hopital Edouard Herriot, Oncologie Médicale, Pavillon E, 5, Place d Arsonval, 69437 Lyon Cedex
    Bull Cancer 93:799-804. 2006
    ..These observations point out the need to introduce translational research as a key element to schedule and evaluate the activity of novel targeted agents in the clinics...
  16. doi request reprint [Edifice program: analysis of screening exam practices for cancer in France]
    J Y Blay
    INSERM U590, Centre Leon Berard, UJOMM HEH and Conticanet FP6 018806, 69373 Lyon, France
    Bull Cancer 95:1067-73. 2008
    ..The objectives of the Edifice study were to analyze a large cohort of patients and doctors in order to further characterize these parameters...
  17. doi request reprint New paradigms in gastrointestinal stromal tumour management
    J Y Blay
    Cytokine and Cancer Unit, Léon Bérard Cancer Centre, Lyon, France
    Ann Oncol 20:i18-24. 2009
    ..Many patients exhibit intolerance or resistance to first-line therapy with imatinib mesylate. Sunitinib malate is approved multinationally for the treatment of advanced imatinib-refractory GIST...
  18. doi request reprint Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations
    Jean Yves Blay
    Cytokine and Cancer Unit, Léon Bérard Cancer Centre, 28 rue Laennec, 69008 Lyon, France
    Expert Rev Anticancer Ther 9:831-8. 2009
    ..This article reviews the evidence underlying the updates to the ESMO recommendations on the management of GIST and discusses the implications of the changes...
  19. doi request reprint Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?
    Jean Yves Blay
    Département de Médecine and Unité INSERM U590, Centre Leon Berard, Lyon, France
    Curr Opin Oncol 21:360-6. 2009
    ..In this setting, the optimal duration of treatment is not known, and it is generally considered that treatment should be given until progression or intolerance...
  20. doi request reprint Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib
    J Y Blay
    Léon Bérard Comprehensive Cancer Centre, Universite Claude Bernard Lyon I, Lyon, France
    Ann Oncol 21:208-15. 2010
    ....
  21. doi request reprint Updating progress in sarcoma therapy with mTOR inhibitors
    J Y Blay
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Ann Oncol 22:280-7. 2011
    ..Design: Reference sources were selected by the author for searches in PubMed and EMBASE, with search terms dependent on the particular subtopic...
  22. doi request reprint Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors
    Jean Yves Blay
    Leon Berard Center, Claude Bernard University, Lyon, France
    Cancer 116:5126-37. 2010
    ..In addition, areas of consensus and points of divergence among the guidelines are highlighted along with any unresolved issues...
  23. doi request reprint A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST
    Jean Yves Blay
    Centre Leon Berard, Lyon, France
    Cancer Treat Rev 37:373-84. 2011
    ..Following progression on these agents, patients have limited treatment options. This critical unmet need is being addressed by the development of new TKIs and the use of novel regimens with approved agents...
  24. doi request reprint Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven
    Jean Yves Blay
    Centre Leon Berard, Medical Oncology Department, 28 rue Laennec, 69008 Lyon, France
    Oncologist 14:1013-20. 2009
    ..We conclude that adjuvant chemotherapy has not been proven to improve the outcome of an unselected population of patients. Several hypotheses are proposed to account for this observation...
  25. ncbi request reprint A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy
    J Y Blay
    Centre L BERARD, Lyon, France
    Blood 92:405-10. 1998
    ..1) from those calculated in the model. This risk index could be useful to identify patients at high risk for chemotherapy-induced thrombocytopenia requiring platelet transfusions...
  26. ncbi request reprint The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group
    J Blay
    PARMA Cooperative Group with Fédération Nationale des Centres de Lutte Contre le Cancer FNCLCC, Dutch Haemato Oncology Working Party HOVON, European Organization for Research and Treatment of Cancer EORTC, Lyon, France
    Blood 92:3562-8. 1998
    ....
  27. ncbi request reprint High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series
    J Y Blay
    Centre Leon Berard, Lyon, France
    J Clin Oncol 16:864-71. 1998
    ..The impact of treatment options on survival and late neurologic toxicity was investigated in a series of patients with primary cerebral lymphoma (PCL) and no known cause of immunosuppression...
  28. ncbi request reprint Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma
    J Y Blay
    Unite Cytokine et Cancer et Département de Médecine, Centre Leon Berard, Lyon, France
    Int J Cancer 72:424-30. 1997
    ....
  29. ncbi request reprint Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens
    J Y Blay
    EORTC Soft Tissue and Bone Sarcoma Group, Brussels, Belgium
    Anticancer Drugs 10:873-7. 1999
    ..Only one patient experienced febrile neutropenia. Raltitrexed as monotherapy is not an effective treatment for patients with ASTS who failed conventional chemotherapy with doxorubicin and ifosfamide...
  30. ncbi request reprint Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
    J Y Blay
    Hospices Civils de Lyon and Ctr L Bérard, Lyon, France
    Eur J Cancer 39:64-9. 2003
    ..Long-term survivors are observed in all prognostic subgroups of patients, in particular those achieving a CR to first-line chemotherapy...
  31. ncbi request reprint High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults
    J Y Blay
    Centre Léon Bérard and Hôpital Edouard Herriot, Lyon, France
    J Clin Oncol 18:3643-50. 2000
    ..The role of high-dose chemotherapy (HDCT) with hematopoietic stem-cell support in this disease is not established...
  32. ncbi request reprint Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer
    J Y Blay
    Centre Leon Berard, Lyon, France
    Ann Oncol 11:39-44. 2000
    ..Primary cerebral non-Hodgkin's lymphomas (NHL) in immunocompetent patients (PCL) are located exclusively in the central nervous system, the eye, or meninges. Clinical management of these patients remains controversial...
  33. pmc Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
    I Ray Coquard
    , Lyon, France
    Br J Cancer 85:816-22. 2001
    ..In conclusion, poor performance status and lymphopenia identify a subgroup of patients at high risk for early death after chemotherapy...
  34. ncbi request reprint [High-dose chemotherapy in soft tissue sarcomas of adults]
    I Ray-Coquard
    , 28, rue Laennec, 69008 Lyon
    Bull Cancer 88:858-62. 2001
    ..Phase III studies are required to confirm that survival may be improved by HDCT in subgroups of patients with ASTS...
  35. ncbi request reprint High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société F
    T Philip
    Centre Leon Berard, Pediatric and Medical Oncology Departement, Lyon, France
    Ann Oncol 10:1065-71. 1999
    ..This study evaluates histological response, long-term outcome, and toxicity in an intensive chemotherapy program given before surgery...
  36. ncbi request reprint Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    Eur J Cancer 39:2021-5. 2003
    ..CNB is accurate, not misleading for s-t-M diagnosis, avoids open biopsy complications, and allows one-surgery or neo-adjuvant chemotherapy planning when combined with appropriate imaging...
  37. doi request reprint A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group
    I Ray-Coquard
    Department of Medical Oncology, Léon Bérard Comprehensive Cancer Center, University of Lyon, and EA 4128 SIS Individu Santé, Société, Lyon, France
    Ann Oncol 20:1105-12. 2009
    ....
  38. pmc A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients
    T Bachelot
    Département de Cancérologie Médicale Centre Léon Bérard, 28 rue Laennec, 69373 Lyon Cedex, France
    Br J Cancer 87:1079-85. 2002
    ..Three patients were alive, free of disease 30 months after completion of the study. Such therapy allows for high-dose intensity and high cumulative doses on a short period of time with manageable toxicity...
  39. ncbi request reprint Sarcomas and malignant phyllodes tumours of the breast--a retrospective study
    C Confavreux
    Centre régional de lutte contre le cancer Léon Bérard, 28 rue Laennec, 69008 Lyon, France
    Eur J Cancer 42:2715-21. 2006
    ..They are composed of a connective tissue stroma and epithelial elements. Pathological presentation ranges from grade I to malignant phyllodes tumours (grade III) where the stromal component clearly exhibits a sarcoma pattern...
  40. pmc Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
    T Bachelot
    Centre Leon Berard, Equipe Cytokines et Cancer, INSERM U 590, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 94:1066-70. 2006
    ..This could have important therapeutic implications with regard to endostatin therapy and raises the question of a possible role of this humoral reaction against endostatin in the neoplastic process...
  41. ncbi request reprint Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients
    P Viens
    Department of Oncology, Institut Paoli Calmettes, 232 Blvd Sainte Marguerite, 13273 Marseille Cedex 9, France
    J Clin Oncol 20:24-36. 2002
    ..To evaluate the safety, pharmacokinetics, and efficacy of three different dose levels of pegylated granulocyte colony-stimulating factor (Ro 25-8315) on progenitor cell mobilization and hematologic recovery in cancer patients...
  42. pmc Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma
    S Negrier
    Department of Medical Oncology, Centre L BERARD, Lyon, France
    Br J Cancer 65:723-6. 1992
    ..Thus, if age does not seem to modify the potential for response to IL2 therapy, cardiac toxicity appears as a limiting factor for intravenous schedules of IL2...
  43. doi request reprint Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    H Ghesquieres
    Department of Hematology, Centre Leon Berard, Universite de Lyon, 28 rue Laennec, Lyon, France
    Ann Oncol 21:842-50. 2010
    ..This prospective multicentric phase II study aimed to confirm the results of the C5R protocol of high-dose methotrexate (MTX)-based chemotherapy (CT) for immunocompetent primary central nervous system lymphoma...
  44. ncbi request reprint Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Ann Oncol 15:307-15. 2004
    ..The primary management of adult soft tissue sarcomas (STS) is characterized by heterogeneity across centers. Several studies suggest that it is improved when coordinated by specialized sarcoma centers...
  45. pmc Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
    T Bachelot
    Unité Cytokine et Cancer, INSERM U 453 and Centre Léon Bérard, 28 rue Laënnec 69008 Lyon, France
    Br J Cancer 88:1721-6. 2003
    ..Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients...
  46. ncbi request reprint Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Cancer 82:134-40. 1998
    ..v.) infusion, and vinorelbine (VNB) was delivered at a dose of 6 mg i.v. bolus followed by VNB, 6 mg/m2/day, in continuous i.v. infusion (Days 1-5) every 21 days...
  47. doi request reprint [Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region]
    F Ducimetière
    Centre Leon Berard, Equipe d évaluation des pratiques médicales, Lyon, France
    Bull Cancer 97:629-41. 2010
    ..Because sarcomas are relatively uncommon yet comprise a wide variety of different entities, second opinion was systematically performed for all included cases...
  48. pmc Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma
    A Ravaud
    Department of Medical Oncology, , Comprehensive Cancer Centre, Bordeaux, France
    Br J Cancer 69:1111-4. 1994
    ..IL-2 and INF-alpha given by this schedule can be safely administered in an outpatient setting. The objective response rate was similar to our previous treatments with high-dose IL-2 given as a continuous infusion...
  49. ncbi request reprint Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients
    K Fizazi
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 16:3736-43. 1998
    ..To assess the outcome and the prognosis of adults with a neoplasm related to the Ewing's sarcoma family of tumors...
  50. doi request reprint Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group
    A Italiano
    Department of Medical Oncology, Institut Bergonie, Bordeaux, France
    Ann Oncol 20:425-30. 2009
    ..There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized synovial sarcoma (SS)...
  51. ncbi request reprint [Chemotherapy of sarcomas: optimization of existing drugs and new molecules]
    J Fayette
    Service d Oncologie Medicale, Pavillon E, Hopital Edouard Herriot, Lyon, France
    Cancer Radiother 10:72-7. 2006
    ..Target therapies and antiangiogenic treatment have also begun to show results. It is advisable from now on to distinguish the different sub-type of sarcomas in order to assess cytotoxic activity...
  52. ncbi request reprint [Soft tissues sarcomas: good medical practices for an optimal management]
    J Fayette
    Service d Oncologie Medicale, Hopital Edouard Herriot, Pavillon E, 5, Place d Arsonval, 69003 Lyon, France
    Cancer Radiother 10:3-6. 2006
    ..Unfortunately, recent studies showed no optimal management for majority of patients treated for sarcomas...
  53. pmc A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region
    P A Cassier
    Department of Medicine, Centre Leon Berard, Lyon, France
    Br J Cancer 103:165-70. 2010
    ..We sought to investigate the molecular epidemiology of sarcomas, including GIST, in the Rhone-Alpes region in France...
  54. ncbi request reprint IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells
    C Menetrier-Caux
    , , , Lyon, France
    Cancer Res 61:3096-104. 2001
    ..Taken together, these results demonstrate that IL-4 and IL-13 reverse the inhibitory effect of tumor cells on DC differentiation...
  55. pmc Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients
    T Philip
    Medical Oncology Department, , Lyon, France
    Br J Cancer 68:1036-42. 1993
    ..This study clearly evidences the selection of the patients receiving immunotherapy and the modification in referrals of a disease induced by a new available therapy. This emphasises the need for prospective studies in this setting...
  56. pmc Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes
    C Menetrier-Caux
    Unité Cytokine et Cancer, Centre Leon Berard, Lyon, France
    Br J Cancer 79:119-30. 1999
    ..These results indicate that RCCs induce IL-10, PGE2 and TNF-alpha production by monocytes, which down-regulate the expression of cell-surface molecules involved in antigen presentation as well as their endocytic capacity...
  57. pmc Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma
    C Bain
    Department of Tumor Biology, , Lyon, France
    Br J Cancer 75:283-6. 1997
    ..008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation...
  58. ncbi request reprint Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinomatosis by liposomal daunorubicin treatment
    A Flechon
    Oncologie Médicale, H pital Edouard Herriot, Lyon, France
    Ann Oncol 12:275-6. 2001
    ..The patient is in complete remission six months after the end of treatment. Liposomal daunorubicin is a promising treatment in the non HIV patient with visceral KS...
  59. ncbi request reprint [Sarcomas of the soft tissues: multidisciplinary approach and new concepts]
    J Fayette
    Hopital Edouard Herriot, Service d Oncologie Medicale, Pavillon E, 5 Place d Arsonval, France
    Rev Med Suisse 1:1979, 1981-4. 2005
  60. ncbi request reprint Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies
    Jeanne L Garnier
    Hĵpital Edouard Herriot, Nephrology, Transplantation and Clinical Immunology Department, Lyon, France
    Recent Results Cancer Res 159:113-22. 2002
    ..We must also improve our understanding of the in vivo mechanisms of action of antibody to develop more efficient antibody constructs...
  61. doi request reprint Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center
    F Lachenal
    Centre Leon Berard, Department of Haematology, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 97:E33-6. 2010
    ..The aim of this study was to analyse practices and factors influencing vaccination in a single centre, in the light of recent literature data...
  62. doi request reprint [Targeted treatment of rare connective tissue tumors and sarcomas]
    P Cassier
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France, Faculté de médecine Lyon I, Universite de Lyon, Place d Arsonval, Lyon, France
    Bull Cancer 97:693-700. 2010
    ..Translational research is and will be an essential tool for the development of new treatments and the identification of the mechanisms of answer and resistance set up by these tumors...
  63. ncbi request reprint Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model
    E Jouanneau
    Neurosurgery Department, Neurological and Neurosurgical Hospital Pierre Wertheimer, Claude Bernard University, Lyon, France
    Cancer Immunol Immunother 55:254-67. 2006
    ..These experimental data may be of importance for the design of clinical trials that currently use multiple DC injections...
  64. doi request reprint [Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin bêta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon
    Bull Cancer 95:433-41. 2008
    ..This article presents a short version of the Recommendations updated in 2007...
  65. ncbi request reprint Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma
    Line Claude
    Department of Radiation Oncology, Hopital Edouard Herriot, Lyon, France
    Radiother Oncol 76:334-9. 2005
    ..To determine overall survival (OS) and independent prognostic factors in patients with brain metastases (BM) from breast cancer treated by whole brain radiotherapy (WBR)...
  66. ncbi request reprint Chemotherapy for osteosarcoma without high-dose methotrexate: another piece in the puzzle
    Jean Yves Blay
    Onkologie 30:226-7. 2007
  67. ncbi request reprint NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
    ....
  68. ncbi request reprint Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
    Paul Lorigan
    Weston Park Hospital, Sheffield, United Kingdom
    J Clin Oncol 25:3144-50. 2007
    ..Combining doxorubicin with standard-dose ifosfamide has not been shown to improve survival and is associated with a significantly increased toxicity; it is not known whether higher dose single-agent ifosfamide is superior to doxorubicin...
  69. doi request reprint Imatinib as a possible cause of severe rhabdomyolysis
    Nicolas Penel
    N Engl J Med 358:2746-7. 2008
  70. ncbi request reprint [Are antiangiogenic antibodies universal for solid tumor?]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 94:S191-6. 2007
    ..This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers...
  71. ncbi request reprint [Angiogenesis and breast cancer]
    Thomas Bachelot
    Centre Leon Berard, Departement de Medecine, 28, rue Laennec, 69373 Lyon Cedex 08
    Bull Cancer 94:S203-10. 2007
    ..This is a review of the major biological and clinical data available on the critical role of angiogenesis in breast cancer. We will also review the different clinical studies reported to date in this area...
  72. doi request reprint [Imatinib and solid tumours]
    Samia Arifi
    unité de jour d oncologie médicale multidisciplinaire, Pavillon E, Hopital Edouard Herriot, 5 Place d Arsonval, 69003 Lyon, France
    Bull Cancer 95:99-106. 2008
    ..We review the current data regarding the activity of imatinib in solid tumors, including GIST...
  73. doi request reprint Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication
    Herve Ghesquieres
    Service d Hematologie Clinique, Centre Leon Berard, Lyon, France
    Hematol Oncol 26:139-47. 2008
    ....
  74. ncbi request reprint [Adjuvant chemotherapy for breast cancer and targeted therapies]
    Armelle Dufresne
    Service d Oncologie Medicale, Hopital Edouard Herriot, Lyon
    Rev Prat 58:477-8. 2008
  75. doi request reprint Imatinib mesilate for the treatment of gastrointestinal stromal tumour
    Philippe A Cassier
    unité de jour d oncologie médicale multidisciplinaire, Pavillon E, Hopital Edouard Herriot, 5 Place d Arsonval, 69003, Lyon, France
    Expert Opin Pharmacother 9:1211-22. 2008
    ..Imatinib mesilate, which was approved in 2002 for the treatment of patients with advanced GIST, has dramatically changed the course of the disease...
  76. doi request reprint A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens
    Isabelle Ray-Coquard
    Centre Léon Bérard and UJOMM H E Herriot, Lyon, France
    Oncologist 13:467-73. 2008
    ..Based on a report showing a specific overexpression of HER-1 in SyS, we investigated an HER-1 inhibitor, gefitinib, in refractory SyS...
  77. ncbi request reprint Emerging drugs for the treatment of soft tissue sarcomas
    Philippe A Cassier
    Unité de Jour Oncologie Médicale Multidisciplinaire, Hopital Edouard Herriot, Lyon, France
    Expert Opin Emerg Drugs 12:139-53. 2007
    ..This review summarises treatment strategies in the context of advanced disease and discusses new compounds being developed for patients with soft tissue sarcomas...
  78. ncbi request reprint Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005
    Jaap Verweij
    Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 43:974-8. 2007
    ..In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity...
  79. ncbi request reprint [Recommendations for the management of GIST patients]
    Jean Yves Blay
    Unité Inserm 590, Centre Leon Berard, 69008 Lyon
    Bull Cancer 92:907-18. 2005
    ..A national consensus meeting was therefore organized in order to identify the optimal management procedures for patients with GIST in localized and advanced stages...
  80. ncbi request reprint Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
    John R Zalcberg
    Department of Medical Oncology, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, VIC 8006, Australia
    Eur J Cancer 41:1751-7. 2005
    ..1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy...
  81. ncbi request reprint Decision making process in oncology practice: is the information available and what should it consist of?
    Jean Tredaniel
    Service d Oncologie Medicale, Hopital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France
    Crit Rev Oncol Hematol 54:165-70. 2005
    ..The study indicates that the information available from reported clinical trials needs to be upgraded and homogenised in order to improve the decision making process in oncology...
  82. ncbi request reprint Targeted cancer therapies
    Jean Yves Blay
    INSERM Unit 590, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Bull Cancer 92:E13-8. 2005
    ..The present paper reviews examples of targeted cancer therapies and their results...
  83. ncbi request reprint [Cancer: epidemiology, carcinogenesis, tumor evolution, classification]
    Jean Yves Blay
    Hopital Edouard Herriot, Lyon
    Rev Prat 54:1935-42. 2004
  84. ncbi request reprint Dendritic cell infiltration and prognosis of early stage breast cancer
    Isabelle Treilleux
    Departments of Pathology, Medicine, Surgery, Radiotherapy and Radiology, and Equipe Cytokines et Cancers INSERM U590 Lyon, France
    Clin Cancer Res 10:7466-74. 2004
    ..Although dendritic cells (DC) and T cells can infiltrate primary breast carcinoma, it remains unclear whether the immune response influences the clinical outcome...
  85. ncbi request reprint [Organization and impact of the multidisciplinary committee in oncology]
    Patrick Castel
    GRESAC, LASS CNRS FRE2747 Centre Léon Bérard, Lyon
    Bull Cancer 91:799-804. 2004
    ..Indeed, this case study shows that the quality of decisions does not only rely on the collective deliberation, but also on the individual and specific competencies of some members of the committee that other members admit...
  86. ncbi request reprint Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor
    Emmanuelle Bompas
    Hopital Edouard Herriot, 5 Place d Arsonval, 69437 Lyon Cedex 03, France
    Leuk Lymphoma 45:2353-4. 2004
    ..Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated...
  87. ncbi request reprint CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer
    Christophe Borg
    INSERM U590, Centre Leon Berard, Lyon, France
    Cancer 101:2675-80. 2004
    ..Lymphopenia is frequently observed in patients with cancer and correlates with the risk of febrile neutropenia and early death after chemotherapy. The phenotype of the depleted lymphocyte populations was investigated in the current study...
  88. ncbi request reprint Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    Jaap Verweij
    Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    Lancet 364:1127-34. 2004
    ..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
  89. pmc Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
    Christophe Borg
    Department of Clinical Biology, Equipe de Recherche Mixte 0208, INSERM, Institut Gustave Roussy, Villejuif, France
    J Clin Invest 114:379-88. 2004
    ..These data point to a novel mode of antitumor action for Gleevec...
  90. ncbi request reprint Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie
    Sylvie Negrier
    Cytokines and Cancer Research Unit, INSERM U 590 and Medical Oncology Department, Cedex 08, France
    J Clin Oncol 22:2371-8. 2004
    ..Our objective was to analyze the prognostic value of circulating vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), and interleukin-6 (IL-6)...
  91. ncbi request reprint Imatinib in patients with metastatic gastrointestinal stromal tumours relapsing after hepatic transplantation
    Emmanuelle Bompas
    Eur J Cancer 40:1456-7. 2004
  92. ncbi request reprint Gastrointestinal stromal tumors: biology and treatment
    Florence Duffaud
    Service d Oncologie Medicale, CHU Timone Adultes, Marseille, France
    Oncology 65:187-97. 2003
    ..Additional follow-up is necessary. Glivec treatment of GIST is the first example of an efficient targeted treatment in a solid tumor...
  93. ncbi request reprint [Anemia and chemotherapy]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 90:S133-43. 2003
    ..In addition, anemia could relieve of specific treatment such as blood transfusion or preventive treatment with recombinant erythropoietin...
  94. ncbi request reprint [Gastro-intestinal stromal tumors: news and comments]
    Isabelle Ray-Coquard
    Clinique Mutualiste Eugène André, Lyon, et Centre Léon Bérard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 90:69-76. 2003
    ..Numerous question regarding the integration of this treatment with surgery and the long term outcome of these patients still remain to be answered however...
  95. ncbi request reprint [Clinical development of anti-angiogenic agents in 2002]
    Thomas Bachelot
    Unité Cytokines et Cancers, INSERM U453, Centre Leon Berard, 28, rue Laennec, 69373 Lyon Cedex 08
    Bull Cancer 90:19-23. 2003
    ..Further clinical trials are needed to gain clear insight into the precise role of those promising strategies for the management of solid tumours...
  96. ncbi request reprint ET-743: a novel agent with activity in soft tissue sarcomas
    Jerome Fayette
    Hopital Edouard Herriot, Medical Oncology Department, Lyon, France
    Oncologist 10:827-32. 2005
    ..Synergy was reported in vitro with doxorubicin and cisplatin; phase I combination studies are in progress...
  97. ncbi request reprint Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis
    Dominique Arpin
    Department of Pneumology, Hopital de la Croix Rousse, 103 Grande Rue de la Croix Rousse, 69317 Lyon Cedex 04, France
    J Clin Oncol 23:8748-56. 2005
    ....
  98. ncbi request reprint Proteasome inhibition: a new approach for the treatment of malignancies
    Jean Philippe Spano
    Departement d Oncologie Medicale, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    Bull Cancer 92:E61-6, 945-52. 2005
    ..This review provides a summary of the rationale for using proteasome inhibitors and an update on available and ongoing clinical studies involving human malignancies...
  99. ncbi request reprint [SOR SAVOIR PATIENT Cancer and fatigue. Information dedicated to cancer patients and relatives]
    Pascale Dielenseger
    Association française des infi rmier e s en cancérologie, Institut Gustave Roussy, Villejuif
    Bull Cancer 93:1213-27. 2006
    ..This article is meant to inform patients and relatives about the disease and its treatments. It also offers health professionals a synthetic evidence-based patient information source which facilitates discussions with the patient...
  100. ncbi request reprint Gastrointestinal stromal tumors (GIST)
    Bruno Landi
    Service d Hepato Gastroenterologie, Hopital Europeen Georges Pompidou, Paris
    Gastroenterol Clin Biol 30:2S98-2S101. 2006
  101. ncbi request reprint Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    Michael Leahy
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK, and Erasmus University Medical Center, Rotterdam, Netherlands
    Eur J Cancer 43:308-15. 2007
    ..In the non-GIST group, this PFS is in the range of other agents considered active in STS, and may predict for more substantial first line activity. Further investigation in STS other than GIST appears warranted...